Jazz Pharmaceuticals receives FDA approval for intravenous administration of Erwinaze®
Jazz Pharmaceuticals announced the FDA approved the intravenous administration of Erwinaze® (asparaginase Erwinia chrysanthemi). Erwinaze is indicated as a component of a multi-agent chemotherapeutic regimen for treatment of patients with ALL. December 19, 2014